Zobrazeno 1 - 10
of 23
pro vyhledávání: '"BORIS M. SELETSKY"'
Autor:
Bruce A. Littlefield, Melvin J. Yu, Yoshito Kishi, Bryan M. Lewis, Xiaojie Zhu, Boris M. Seletsky, Wanjun Zheng, Kimberley K. Aalfs, Bruce F. Wels, Kathleen A. Salvato, Murray J. Towle
Supplementary Figures S1-S4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca24a570431d08fbc8d5c6fc05689ec0
https://doi.org/10.1158/0008-5472.22385954.v1
https://doi.org/10.1158/0008-5472.22385954.v1
Autor:
JOHN Malona, CLAUDIO CHUAQUI, BORIS M. SELETSKY, LISA BEEBE, SUSAN CANTIN, DANIEL VAN KALKEN, KELLY FAHNOE, ZHIGANG WANG, BETH BROWNING, HILARY SZABO, LOUISE A. KOOPMAN, TAMAS ORAVECZ, JOSEPH J. MCDONALD, FRANCISCO RAMIREZ-VALLE, RAJULA GAUR, KOFI A. MENSAH, MICHAEL THOMAS, JAMIE N. CONNARN, HAIQING HU, MATTHEW D. ALEXANDER, ALAN F. CORIN
Publikováno v:
Translational research : the journal of laboratory and clinical medicine. 249
As an anti-inflammatory strategy, MAPK-activated protein kinase-2 (MK2) inhibition can potentially avoid the clinical failures seen for direct p38 inhibitors, especially tachyphylaxis. CC-99677, a selective targeted covalent MK2 inhibitor, employs a
Autor:
Yongbo Hu, Hong Du, Melvin J. Yu, Yimin Jiang, Bruce A. Littlefield, Wanjun Zheng, Sridhar Narayan, Carlson Eric, Bryan M. Lewis, Huiming Zhang, Murray J. Towle, Karen TenDyke, Boris M. Seletsky, Hongsheng Cheng
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:1630-1633
Eribulin mesylate (Halaven™), a totally synthetic analog of the marine polyether macrolide halichondrin B, has recently been approved in the United States as a treatment for breast cancer. It is also currently under regulatory review in Japan and t
Autor:
Boris M. Seletsky, Karen TenDyke, Sean Eckley, Bruce A. Littlefield, Huiming Zhang, Hong Du, Carlson Eric, Wanjun Zheng, Yimin Jiang, Sridhar Narayan, Murray J. Towle, Yongbo Hu, Edgar Schuck, Krista Condon, Vipul Kumar, Hongsheng Cheng, Bryan M. Lewis, Philip Saxton, Melvin J. Yu
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:1639-1643
Novel second generation analogs of eribulin mesylate, a tubulin agent recently approved for the treatment of breast cancer, are reported. Our recent efforts have focused on expanding the target indications for this class of compounds to other tumor t
Autor:
Charles-André Lemelin, Boris M. Seletsky, Kimberley K. Aalfs, Paul J. Lydon, Davis Heather, Yoshito Kishi, Kathleen A. Salvato, Bruce A. Littlefield, Lynda Tremblay, Murray J. Towle, Charles E. Chase, Yongchun Shen, Lori A. Singer, Melvin J. Yu, Wanjun Zheng, Bruce F. Wels, Monica Palme
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 14:5551-5554
Structurally simplified macrocyclic ketone analogues of halichondrin B were prepared by total synthesis and found to retain the potent cell growth inhibitory activity in vitro, stability in mouse serum, and in vivo efficacy of the natural product.
Publikováno v:
Angewandte Chemie. 112:983-986
Publikováno v:
Angewandte Chemie International Edition. 39:953-956
Publikováno v:
ChemInform. 44
Covering: 1993 to 2002The synthesis of eribulin mesylate from microgram to multi-gram scale is described in this Highlight. Key coupling reactions include formation of the C30a to C1 carbon–carbon bond and macrocyclic ring closure through an intram
Publikováno v:
Natural product reports. 30(9)
Covering: 1993 to 2002The synthesis of eribulin mesylate from microgram to multi-gram scale is described in this Highlight. Key coupling reactions include formation of the C30a to C1 carbon–carbon bond and macrocyclic ring closure through an intram
Publikováno v:
The Journal of Organic Chemistry. 59:3413-3420
Additions of the γ-alkoxy allylic stannanes (S)-1 and (R)-1 and the racemate (RS)-1 to the threose and erythrose aldehyde derivatives 6 and 15 in the presence of BF 3 -OEt 2 or MgBr 2 .OEt 2 were examined in order to establish stereochemical prefere